Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2010 Jan 28;287(2):216-23. doi: 10.1016/j.canlet.2009.06.016. Epub 2009 Jul 25.

Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death.

Author information

  • 1Departamento de Morfología y Biología Celular, Spain. martinvanesa@uniovi.es

Abstract

Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.

Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

PMID:
19632770
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk